Member Info for Marty130

GENF has a monthly cash burn of £160k, perhaps they will be forced to cut this down..

OTC possibly.

The poser here is what high value translates to, in terms of share price m/cap?

Genflow dog gene therapy value

+5

Genflow Biosciences' (LSE:GENF) dog gene therapy (GF-1002) trial shows high value, with positive interim results indicating improved survival, reduced frailty, and better muscle mass in aged dogs. As of February 2026, the company is leveraging these findings, backed by a €4 million grant, to potentially license the therapy to animal health partners.

So the raise was agreed!

All this mess going on in the middle east, hasn't helped.. Oil price has jumped..

They will probaly release some good news tomorrow, before they dilute.

Https://finance.yahoo.com/news/genflow-biosciences-plc-announces-notice-070000007.html

Genflow Biosciences (LSE: GENF) announced on February 11, 2026, that it is seeking shareholder approval for a potential equity raise through a General Meeting scheduled for March 2, 2026. This move, which would involve issuing up to 188,947,368 new shares (approximately 38% of current capital), could lead to significant shareholder dilution and downward pressure on the share price in the short term.

Investegate

+2

Here is a breakdown of the potential impacts on the share price based on the announced, pending, and previous, smaller equity raises:

Short-Term Price Pressure (Dilution): As of early 2026, shareholders have faced substantial dilution. A potential raise of ~38% of the company's capital is a significant expansion, which historically leads to a lower valuation per share, even if the total market cap stays similar.

Purpose of Funds (Long-Term Potential): The proceeds are intended to fund the MASH program's IND-enabling stage, animal health payments for the beagle dog trials, and glaucoma proof-of-concept studies. If investors believe these funds will successfully advance the pipeline, the stock could recover in the long term.

Immediate Share Price Context: As of late February 2026, the share price has been trading around 2.00p. The announcement of the potential raise caused volatility, with the price fluctuating in the days following the announcement.

Previous Similar Actions: Genflow has completed smaller follow-on equity offerings in the past (e.g.£0.34m£0.715m), which highlight a consistent need for new capital to fund research, typical of clinical-stage biotech companies.

Investegate

+7

Conclusion:

The announcement of the potential equity raise introduces uncertainty and, if implemented, will cause immediate, significant dilution to existing shareholders. However, the move is aimed at financing critical research milestones, which is necessary for the company’s long-term growth potential

Sorry same monica....

Nice cut N Paste from advfn.

lol..

Why has this risen so high today? Is it down to a consolidation?

First Equity Limited, acting as investment manager for Armstrong Investments Limited, has acquired a significant stake in Renalytix PLC, now holding 3.157760% of the company's voting rights, which equates to 13,800,000 shares. This notification follows an acquisition or disposal of voting rights and was made on February 26, 2026, with the threshold being crossed on February 25, 2026. The estate of William Black is identified as the ultimate controlling person in this chain of holdings.

Genflow Biosciences PLC (GENF) has announced a General Meeting (GM), rather than an Annual General Meeting (AGM), scheduled for March 2026 to discuss financing for its 2026 strategic priorities.

Yahoo Finance UK

+1

Key Details of the March 2026 Meeting:

Date: Monday, 2 March 2026

Time: 11:00 AM

Location: One Heddon Street, London, W1B 4BD

Purpose: The Board is seeking authorization to dis-apply statutory pre-emption rights to facilitate a "Potential Equity Raise".

Use of Proceeds: Funds from this potential raise would support:

Moving the MASH (Metabolic Dysfunction-Associated Steatohepatitis) program to the IND-enabling stage.

Final payments for the randomized clinical trial in aged beagle dogs.

Glaucoma Proof of Concept studies.

Finalizing EU patent approval and advancing US patent applications.

FirstWord Pharma

+3

2026 Strategic Outlook:

Partnerships: CEO Dr. Eric Leire highlighted that 2026 is focused on data partnerships and capital efficiency.

Key Data: The company expects results from its dog ageing study in early 2026.

Financial Strategy: The proposed equity raise is intended to provide negotiating leverage for potential partnerships, ensuring the company does not have to accept unfavorable terms.

Good to see large buys taking place

Thanks, most informative. GL.

Not making anything up, I always carry out research online and from my brokers.

Genflow Biosciences is looking for pharmaceutical partners for its gene therapy, but they are not listed as partnering with Bayer in the provided results.

Bayer is actively working on gene editing and therapy, including collaborations with CRISPR

One of the companies could well be Bayer, massive animal health company. Deals could go into many, many millions.

LONDON - Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) announced Monday it has signed two Confidential Disclosure Agreements with leading animal health companies to explore potential collaborations based on its SIRT6-centenarian gene therapy platform.

The agreements will facilitate data exchange and discussions on partnership opportunities focused on extending healthspan in companion animals. This development follows Genflow’s ongoing GF-1004 Dog Aging study in beagles, which the company reports has shown no adverse events to date.

The CDAs represent a step in Genflow’s strategy to apply its gene therapy technology to both human and animal health markets. The company aims to leverage these potential partnerships to accelerate commercialization and market entry.

"The signing of these CDAs reflects strong industry interest in our longevity platform and represents a further step toward building strategic partnerships in animal health," said Dr. Eric Leire, CEO of Genflow, in the press release.

Genflow, founded in 2020 and headquartered in the UK with R&D facilities in Belgium, is developing gene therapies focused on decelerating the aging process. The company’s lead compound, GF-1002, delivers a centenarian variant of the SIRT6 gene.

In addition to its canine aging study that began in March 2025, Genflow plans to initiate a clinical trial exploring GF-1002’s potential benefits in treating Metabolic Dysfunction-Associated Steatohepatitis (MASH), a prevalent chronic liver disease.

The company describes the companion animal market as "rapidly growing and high-value," suggesting these partnerships could provide access to global scale, regulatory expertise, and commercial infrastructure.